Topics and Trends in Most Cited Estrogen and related hormone effects Papers

Ranked by citations 18 months after publication

Class of 2026 (Papers Published in 2024)

What topics and trends defined most-cited Estrogen and related hormone effects research in the Class of 2026?

Research in the Class of 2026 centers on menopausal hormone therapy and targeted breast cancer care. Menopause and coronary heart disease risk saw major increases, while estradiol and selective estrogen receptor degraders gained momentum. Conversely, traditional aromatase inhibitors declined sharply as attention shifted toward novel combination therapies and precision cardiometabolic risk management.

See details ↓

Updated July 31, 2026

At a glance

Field
Estrogen and related hormone effects
Cohort label
Class of 2026 (2024 publications)
Papers analyzed
2,723
Papers ranked
20
Top topics in ranked papers
Menopause, menopausal hormone therapy, advanced breast cancer, CDK4/6 inhibitors, SERDs
Publication window
Jan 1, 2024 – Dec 31, 2024
Eligibility
Research articles; reviews excluded
Citation window
18 months post-publication
18m citation range
25–70
Data source
OpenAlex · Retrieved Jul 2026
License
CC BY 4.0

Rankings

20 papers ranked by 18-month citation count

#1 of 2,723
7018m citations

Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause

JoAnn V Pinkerton et al.JAMA202410.1001/jama.2024.14618

JoAnn V. PinkertonUniversity of Virginia Health, United States

elinzanetantneurokinin receptor antagonisthot flashesOASIS 1 trialOASIS 2 trialelectronic hot flash daily diaryPatient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8bMenopause-Specific Quality of Life questionnaireVMS frequency reductionVMS severity reductionsleep disturbancesnonhormonal treatmentmenopause
Badge
#2 of 2,723
7018m citations

Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial

Mafalda Oliveira et al.The Lancet Oncology202410.1016/s1470-2045(24)00387-5

Mafalda OliveiraVall d'Hebron Institute of Oncology, Spain

Camizestrantselective estrogen receptor degraderfulvestrantestrogen receptor-positive breast cancerHER2-negative breast canceradvanced breast cancermenopauseSERENA-2phase 2 trialmulti-dose comparison
Badge
#4 of 2,723
6418m citations

Elacestrant in ER+, HER2− Metastatic Breast Cancer with <i>ESR1</i> -Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups

Aditya Bardia et al.Clinical Cancer Research202410.1158/1078-0432.ccr-24-1073

Aditya BardiaUniversity of California Los Angeles, United States

elacestrantESR1 mutationER+ HER2- metastatic breast cancerCDK4/6 inhibitorEMERALD trialProgression-free survivalresistancefulvestrantaromatase inhibitorESR1 D538G mutationESR1 Y537S/N mutationPIK3CA mutationTP53 mutationHER2-lowBone metastasesliver and lung metastasesprior treatment durationselective estrogen receptor degrader
Badge
#5 of 2,723
6018m citations

Menopausal Hormone Therapy Use Among Postmenopausal Women

Lin Yang et al.JAMA Health Forum202410.1001/jamahealthforum.2024.3128

Lin Yang, Adetunji T. ToriolaAlberta Health Services, Canada

menopausal hormone therapymenopauseNational Health and Nutrition Examination Surveyserial cross-sectional analysisMHT use trendsprescription medication dataEstrogen monotherapyRacial and ethnic disparitiesnon-Hispanic White womennon-Hispanic Black womenHispanic womenage-stratified prevalencefamily income-to-poverty ratiohealth insurance coveragemenopausal symptoms
Badge
#7 of 2,723
5118m citations

Hallmarks of female reproductive aging in physiologic aging mice

Julia L Balough, Shweta S Dipali, Karen Velez et al.Nature Aging202410.1038/s43587-024-00769-y

Francesca E. DuncanBuck Institute for Research on Aging, United States

Female reproductive agingphysiologic aging miceoocyte quality declinefollicular depletionHormonal changesestrous cycle irregularityage-related infertilityovarian reservegranulosa cell dysfunctionmitochondrial dysfunction in oocytesDNA damage accumulationaneuploidyspindle assembly checkpointoxidative stressinflammatory signalingextracellular matrix remodelingvascular changes in ovaryprimordial follicle activation
Badge
#8 of 2,723
4618m citations

Estrogen and cardiovascular disease

Felice Gersh et al.Progress in Cardiovascular Diseases202410.1016/j.pcad.2024.01.015

Felice L GershUniversity of Arizona, United States

estrogencardiovascular diseasemenopausal hormone therapyCoronary heart diseasemenopauseestrogen receptoratherosclerosisendothelial functionLipid profilestroke riskcardioprotective effectsWomen's Health Initiative
Badge
#9 of 2,723
4618m citations

In vivo brain estrogen receptor density by neuroendocrine aging and relationships with cognition and symptomatology

Lisa Mosconi et al.Scientific Reports202410.1038/s41598-024-62820-7

Lisa MosconiWeill Cornell Medicine, United States

estradiolestrogen receptorneuroendocrine aging18F-fluoroestradiol PETmenopauseestrogen receptor expressionmemory performanceestrogen-regulated networksserum estradiol levelsex hormone binding globulinmidlife womenCognitive symptomsmood symptomsin vivo neuroimagingbrain agingcognitive function
Badge
#10 of 2,723
4318m citations

Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial

Therese Johansson et al.BMJ202410.1136/bmj-2023-078784

Therese JohanssonUppsala University, Sweden

menopausal hormone therapyemulated target trialSwedish national registriesoral combined continuous therapyoral combined sequential therapyoral unopposed oestrogentransdermal estrogentibolonevenous thromboembolismCoronary heart diseasecerebral infarctionmyocardial infarctionRoute of administrationestrogen-progestogen therapylocal progestinintention-to-treat analysisper protocol analysisCardiovascular disease riskhormone combination effects
Badge
#11 of 2,723
3918m citations

Menopause transition and cardiovascular disease risk

Erin R Uddenberg et al.Maturitas202410.1016/j.maturitas.2024.107974

Chrisandra ShufeltMayo Clinic, United States

menopauseCardiovascular disease riskestrogen declinelipid profile changesendothelial dysfunctionarterial stiffnessCoronary heart diseasemenopausal hormone therapymetabolic syndromehot flashesatherosclerosisinflammatory markersmenopausal hormone therapy timing hypothesis
Badge
#12 of 2,723
3618m citations

Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial

Mafalda Oliveira et al.The Lancet Oncology202410.1016/s1470-2045(24)00373-5

Mafalda OliveiraVall d'Hebron University Hospital, Spain

capivasertibfulvestranthormone receptor-positive breast cancerHER2-negative breast canceradvanced breast cancerCAPItello-291patient-reported outcomesphase 3 trialAKT inhibitorendocrine therapy combinationquality of life assessmentRandomized double-blind placebo-controlled trial
Badge
#13 of 2,723
3518m citations

Assessing male reproductive toxicity of environmental pollutant di-ethylhexyl phthalate with network toxicology and molecular docking strategy

Yanggang Hong et al.Reproductive Toxicology202410.1016/j.reprotox.2024.108749

Yanggang HongWenzhou Medical University, China

Di-ethylhexyl phthalatemale reproductive toxicityenvironmental pollutantnetwork toxicologymolecular dockingphthalate exposurereproductive endpointstoxicity assessmentcomputational toxicologyprotein-ligand bindingtoxicological networksEndocrine disruptiontesticular toxicityspermatogenesisandrogen signaling
Badge
#14 of 2,723
3318m citations

Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study

Miguel Martín et al.Journal of Clinical Oncology202410.1200/jco.23.01500

Miguel MartínHospital Gregorio Marañón, Spain

giredestrantestrogen receptor-positive breast cancerHER2-negative breast canceradvanced breast canceracelERA BC studyphysician's choice of endocrine monotherapyfulvestrantaromatase inhibitorProgression-free survivalESR1 mutationcirculating tumor DNACDK4/6 inhibitorGnRH agonistvisceral diseaseselective estrogen receptor degrader
Badge
#15 of 2,723
2918m citations

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

E Hamilton et al.Annals of Oncology202410.1016/j.annonc.2024.04.012

Richard D. BairdSarah Cannon Research Institute, United States

Camizestrantselective estrogen receptor degraderestrogen receptor-positive breast cancerHER2-negative breast canceradvanced breast cancerphase I trialdose escalationdose expansionSERENA-1Estrogen monotherapy
Badge
#16 of 2,723
2918m citations

Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial

Carlo Palmieri et al.The Lancet Oncology202410.1016/s1470-2045(24)00004-4

Carlo PalmieriThe University of Liverpool, United Kingdom

enobosarmselective androgen receptor modulatorandrogen receptorestrogen receptor-positive breast cancerHER2-negative breast cancerAR-positive diseaseER-positive advanced breast cancerandrogen receptor as tumour suppressorclinical benefit ratemenopauseadvanced breast cancerAR activationdrug-induced liver injuryhypercalcaemiaendocrine therapyBone metastasesphase 2 trial
Badge
#17 of 2,723
2818m citations

Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer

M T Herrera-Abreu et al.Nature Communications202410.1038/s41467-024-53837-7

Ciara Metcalfe, Nicholas C. TurnerThe Institute of Cancer Research, United Kingdom

GPX4CDK4/6 inhibitorendocrine therapyestrogen receptor positive breast cancerpalbociclibgiredestrantFerroptosisgenome-wide CRISPR screensoxidative stresslipid peroxidationAGPAT3ACSL4triple negative breast cancerCDK4/6 inhibitor resistancelipid metabolismperoxisomeCytostasisGPX4 inhibition
Badge
#18 of 2,723
2618m citations

Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses

Seo H Baik et al.Menopause The Journal of The North American Menopause Society202410.1097/gme.0000000000002335

Seo Hyon BaikUS National Institutes of Health, United States

menopausal hormone therapy beyond age 65Medicare prescription drug and encounter recordsTime-dependent Cox proportional hazards regressionEstrogen monotherapyestrogen-progestogen therapytransdermal estrogenvaginal estrogenoral estrogenconjugated equine estrogenestradiolall-cause mortalitybreast cancer riskendometrial cancercolorectal cancercongestive heart failure (CHF)venous thromboembolismCoronary heart diseasedementia riskdose-response relationship
Badge
#19 of 2,723
2618m citations

Exploring the role of trifarotene against RAR-α: an investigation of expression pattern and clinicopathological significance of RAR-α in breast cancer

Nusrat Jan et al.Frontiers in Pharmacology202410.3389/fphar.2024.1361679

Manzoor Ahmad MirUniversity of Kashmir, India

RAR-αtrifaroteneretinoic acid receptorsretinoid X receptorsretinoic acid-responsive elementsRAR-RXR heterodimersretinoic acidbreast cancerRAR-α overexpressionUALCANTISCHTIMER 2.0ENRICHRIn-silico drug screeninggranulocyte differentiationretinoic acid receptor signaling pathwaycellular response to estrogen stimuluscytotoxicity assaymolecular docking
Badge
#20 of 2,723
2518m citations

Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer

Stephanie W Vrede et al.Gynecologic Oncology202410.1016/j.ygyno.2024.10.028

Stephanie VredeRadboud University Medical Center, Netherlands

estrogen receptorprogesterone receptormolecular classificationPOLEmutMismatch repair deficient (MMRd)TP53 mutationthree-tiered risk modelimmunohistochemical expressionnext-generation sequencingDisease-specific survivallympho-vascular space invasionFIGO stagePrognostic biomarkerendometrial cancer
Badge

Dominant research themes and year-over-year shifts in Estrogen and related hormone effects

What Topics Define the Class of 2026?

The Class of 2026 cohort in estrogen and related hormone research is driven by two major pillars: postmenopausal hormone therapy alongside women's cardiometabolic health, and targeted therapeutic strategies for hormone receptor-positive (HR+) advanced breast cancer. Menopause and menopausal hormone therapy (MHT) dominate the landscape, appearing in 28% and 18% of top-ranked publications respectively. High-impact investigations focus on clarifying long-term cardiovascular risks, cognitive function, and individual risk-benefit profiles associated with systemic MHT and estrogen monotherapy. Estradiol signaling and sex hormone-binding globulin (SHBG) emerge as key physiological biomarkers for metabolic and endocrine assessment in aging populations. In parallel, oncology research centers heavily on targeted interventions for advanced and HER2-negative breast cancer. Selective estrogen receptor degraders (SERDs), such as fulvestrant and novel oral agents, along with CDK4/6 inhibitors remain central clinical focal points. Studies evaluate combination regimens aimed at overcoming endocrine resistance, managing hot flashes, and tailoring risk stratifications for estrogen receptor-positive disease. Together, these focal points reflect a dual clinical focus: optimizing long-term systemic hormone safety during menopausal transitions while refining endocrine and targeted therapies for estrogen-driven malignancies.

Leading research themes
Leading research themes

How Did Topics Shift from the Class of 2025 to the Class of 2026?

Comparing the Class of 2025 to the Class of 2026 reveals significant thematic shifts in estrogen research, characterized by a surging interest in postmenopausal health outcomes and a strategic pivot in oncology therapeutics. The most prominent growth occurred in menopausal hormone therapy and postmenopausal risk assessment. Menopause research rose by 10 percentage points (from 18% to 28%), while coronary heart disease emerged sharply as a major focal area (reaching 10% of ranked literature from zero in the previous cohort). Estradiol evaluation (+6 percentage points) and breast cancer risk modeling (+8 percentage points) also recorded strong upward momentum, driven by large-scale clinical trials and colocalization analyses examining systemic hormone exposure. Conversely, traditional monotherapies and older treatment frameworks experienced noticeable declines. Aromatase inhibitors saw the steepest drop, falling from 18% in 2025 down to 6% in 2026 (-12 percentage points), reflecting a transition toward next-generation combination therapies. Generic hormone receptor-positive breast cancer classifications also contracted as studies adopted more granular molecular subtyping, such as HER2-negative and ESR1-mutated designations. These shifts highlight a field broadening its scope beyond localized tumor suppression toward comprehensive cardiovascular risk management, precision risk stratification, and novel SERD-based therapeutic regimens.

How topics shifted year over year
How topics shifted year over year
Methodology

PRI identifies high-impact research using a transparent, topic-agnostic framework applied consistently across scientific domains. Bibliographic records are drawn from OpenAlex, including publication dates, citation relationships, and document types.

This ranking covers the Class of 2026 cohort: journal articles published in 2024. Reviews and other non-article document types are excluded to ensure comparability.

Research impact is quantified with an 18-month post-publication citation window—the number of citing works published within 18 months of each paper's publication date. This metric captures early impact while controlling for publication age.

An LLM-based relevance classifier then reviews each candidate's title and abstract to confirm substantive alignment with the target domain. Only papers classified as relevant appear in the final ranking.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459

Full methodologyGitHubbioRxiv preprint

Cite this ranking

Pepkio Research Index (PRI). Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026. https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026. Accessed 2026-07-31.

Methodology
Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459